PARP and other prospective targets for poisoning cancer cell metabolism

Biochemical Pharmacology

Volumn 92, Issue 1, 2014, Pages 164-171

  Michels, Judith ^a,b   Obrist, Florine ^a,b,c   Castedo, Maria ^a,b   Vitale, Ilio ^d   Kroemer, Guido ^a,b,e,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Autophagy; Mitochondria; NADPH; PARP 1; Sirtuin

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOLYTIC ENZYME; LACTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REACTIVE OXYGEN METABOLITE; SIRTUIN; PARP1 PROTEIN, HUMAN;

ACIDIFICATION; AEROBIC GLYCOLYSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CELL METABOLISM; CELL SURVIVAL; DETOXIFICATION; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENOMIC INSTABILITY; GLUCOSE METABOLISM; GLYCOLYSIS; HOMEOSTASIS; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; HUMANS; NAD; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84908210107     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.08.026     Document Type: Review

References (154)

1. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
2. W.H. Koppenol, P.L. Bounds, and C.V. Dang Otto Warburg's contributions to current concepts of cancer metabolism Nat Rev Cancer 11 2011 325 337
3. S.Y. Lunt, and M.G. Vander Heiden Aerobic glycolysis: meeting the metabolic requirements of cell proliferation Annu Rev Cell Dev Biol 27 2011 441 464
4. L. Galluzzi, O. Kepp, M.G. Vander Heiden, and G. Kroemer Metabolic targets for cancer therapy Nat Rev Drug Discov 12 2013 829 846
5. J. Son, C.A. Lyssiotis, H. Ying, X. Wang, S. Hua, and M. Ligorio Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway Nature 496 2013 101 105
6. A. Schulze, and A.L. Harris How cancer metabolism is tuned for proliferation and vulnerable to disruption Nature 491 2012 364 373
7. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
8. A.G. Ladurner Rheostat control of gene expression by metabolites Mol Cell 24 2006 1 11
9. M.G. Vander Heiden, J.W. Locasale, K.D. Swanson, H. Sharfi, G.J. Heffron, and D. Amador-Noguez Evidence for an alternative glycolytic pathway in rapidly proliferating cells Science 329 2010 1492 1499
10. M.G. Vander Heiden, D.R. Plas, J.C. Rathmell, C.J. Fox, M.H. Harris, and C.B. Thompson Growth factors can influence cell growth and survival through effects on glucose metabolism Mol Cell Biol 21 2001 5899 5912
11. K.M. Holmstrom, and T. Finkel Cellular mechanisms and physiological consequences of redox-dependent signalling Nat Rev Mol Cell Biol 15 2014 411 421
12. J.D. Pennington, T.J. Wang, P. Nguyen, L. Sun, K. Bisht, and D. Smart Redox-sensitive signaling factors as a novel molecular targets for cancer therapy Drug Resist Updates 8 2005 322 330
13. C. Gorrini, I.S. Harris, and T.W. Mak Modulation of oxidative stress as an anticancer strategy Nat Rev Drug Discov 12 2013 931 947
14. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach Nat Rev Drug Discov 8 2009 579 591
15. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat Rev Cancer 11 2011 85 95
16. H. Ying, A.C. Kimmelman, C.A. Lyssiotis, S. Hua, G.C. Chu, and E. Fletcher-Sananikone Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism Cell 149 2012 656 670
17. D.R. Wise, R.J. DeBerardinis, A. Mancuso, N. Sayed, X.Y. Zhang, and H.K. Pfeiffer Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Proc Natl Acad Sci U S A 105 2008 18782 18787
18. R.L. Elstrom, D.E. Bauer, M. Buzzai, R. Karnauskas, M.H. Harris, and D.R. Plas Akt stimulates aerobic glycolysis in cancer cells Cancer Res 64 2004 3892 3899
19. C. Munoz-Pinedo, N. El Mjiyad, and J.E. Ricci Cancer metabolism: current perspectives and future directions Cell Death Dis 3 2012 e248
20. X.L. Zu, and M. Guppy Cancer metabolism: facts, fantasy, and fiction Biochem Biophys Res Commun 313 2004 459 465
21. R.D. Goldman, N.O. Kaplan, and T.C. Hall Lactic dehydrogenase in human neoplastic tissues Cancer Res 24 1964 389 399
22. H. Shim, C. Dolde, B.C. Lewis, C.S. Wu, G. Dang, and R.A. Jungmann c-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proc Natl Acad Sci U S A 94 1997 6658 6663
23. W. Lu, Y. Hu, G. Chen, Z. Chen, H. Zhang, and F. Wang Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy PLoS Biol 10 2012 e1001326
24. W.J. Israelsen, T.L. Dayton, S.M. Davidson, B.P. Fiske, A.M. Hosios, and G. Bellinger PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells Cell 155 2013 397 409
25. Y. Jiang, X. Li, W. Yang, D.H. Hawke, Y. Zheng, and Y. Xia PKM2 regulates chromosome segregation and mitosis progression of tumor cells Mol Cell 53 2014 75 87
26. K.C. Patra, Q. Wang, P.T. Bhaskar, L. Miller, Z. Wang, and W. Wheaton Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer Cancer Cell 24 2013 213 228
27. D. Anastasiou, G. Poulogiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, and M. Shen Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses Science 334 2011 1278 1283
28. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, and R. Wei The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233
29. H.R. Christofk, M.G. Vander Heiden, N. Wu, J.M. Asara, and L.C. Cantley Pyruvate kinase M2 is a phosphotyrosine-binding protein Nature 452 2008 181 186
30. N. Karachaliou, C. Papadaki, E. Lagoudaki, M. Trypaki, M. Sfakianaki, and A. Koutsopoulos Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPOmicron-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide PLOS ONE 8 2013 e74611
31. L. Xiao, Z.Y. Hu, X. Dong, Z. Tan, W. Li, and M. Tang Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy Oncogene 2014 [Epub ahead of print]
32. D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, and H. Pelicano Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate Cancer Cell 10 2006 241 252
33. +: an old metabolite controlling new metabolic signaling pathways Endocr Rev 31 2010 194 223
34. A. Rongvaux, R.J. Shea, M.H. Mulks, D. Gigot, J. Urbain, and O. Leo Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis Eur J Immunol 32 2002 3225 3234
35. N. Hara, K. Yamada, T. Shibata, H. Osago, T. Hashimoto, and M. Tsuchiya Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells J Biol Chem 282 2007 24574 24582
36. + precursor quinolinic acid confers resistance of gliomas to oxidative stress Cancer Res 73 2013 3225 3234
37. M.O. Hottiger, P.O. Hassa, B. Luscher, H. Schuler, and F. Koch-Nolte Toward a unified nomenclature for mammalian ADP-ribosyltransferases Trends Biochem Sci 35 2010 208 219
38. R.H. Houtkooper, E. Pirinen, and J. Auwerx Sirtuins as regulators of metabolism and healthspan Nat Rev Mol Cell Biol 13 2012 225 238
39. M. Roth, and W.Y. Chen Sorting out functions of sirtuins in cancer Oncogene 33 2014 1609 1620
40. E.N. Chini CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions Curr Pharm Des 15 2009 57 63
41. C.L. Brooks, and W. Gu How does SIRT1 affect metabolism, senescence and cancer Nat Rev Cancer 9 2009 123 128
42. P. Bai, and C. Canto The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease Cell Metab 16 2012 290 295
43. S. Sahar, and P. Sassone-Corsi Metabolism and cancer: the circadian clock connection Nat Rev Cancer 9 2009 886 896
44. D. Neri, and C.T. Supuran Interfering with pH regulation in tumours as a therapeutic strategy Nat Rev Drug Discov 10 2011 767 777
45. S.K. Parks, J. Chiche, and J. Pouyssegur Disrupting proton dynamics and energy metabolism for cancer therapy Nat Rev Cancer 13 2013 611 623
46. + symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors Proc Natl Acad Sci U S A 108 2011 16663 16668
47. D. Trachootham, W. Lu, M.A. Ogasawara, R.D. Nilsa, and P. Huang Redox regulation of cell survival Antioxid Redox Signal 10 2008 1343 1374
48. C.V. Dang Rethinking the Warburg effect with Myc micromanaging glutamine metabolism Cancer Res 70 2010 859 862
49. P. Gao, I. Tchernyshyov, T.C. Chang, Y.S. Lee, K. Kita, and T. Ochi c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature 458 2009 762 765
50. R.J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, and S. Wehrli Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis Proc Natl Acad Sci U S A 104 2007 19345 19350
51. L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, and E.M. Driggers Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
52. P. Guilhamon, M. Eskandarpour, D. Halai, G.A. Wilson, A. Feber, and A.E. Teschendorff Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 Nat Commun 4 2013 2166
53. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, and O. Kepp Molecular mechanisms of cisplatin resistance Oncogene 31 2012 1869 1883
54. L. Sawers, M.J. Ferguson, B.R. Ihrig, H.C. Young, P. Chakravarty, and C.R. Wolf Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines Br J Cancer 2014 [Epub ahead of print]
55. H.H. Chen, and M.T. Kuo Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy Met Based Drugs 2010 2010
56. J. Carmichael, L.M. Forrester, A.D. Lewis, J.D. Hayes, P.C. Hayes, and C.R. Wolf Glutathione S-transferase isoenzymes and glutathione peroxidase activity in normal and tumour samples from human lung Carcinogenesis 9 1988 1617 1621
57. A.D. Lewis, J.D. Hayes, and C.R. Wolf Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects Carcinogenesis 9 1988 1283 1287
58. K. Liu, X. Lin, Q. Zhou, T. Ma, L. Han, and G. Mao The associations between two vital GSTs genetic polymorphisms and lung cancer risk in the Chinese population: evidence from 71 studies PLOS ONE 9 2014 e102372
59. Z. Wang, H. Xu, M. He, H. Wu, Y. Zhu, and Z. Su The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis Eur J Cancer Care (Engl) 2014 [Epub ahead of print]
60. R. Zhang, K.A. Kang, M.J. Piao, K.C. Kim, J. Zheng, and C.W. Yao Epigenetic alterations are involved in the overexpression of glutathione S-transferase pi-1 in human colorectal cancers Int J Oncol 45 2014 1275 1283
61. H.W. Kang, P.H. Song, Y.S. Ha, W.T. Kim, Y.J. Kim, and S.J. Yun Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients Eur J Cancer 49 2013 3010 3019
62. R. Krishnakumar, and W.L. Kraus The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets Mol Cell 39 2010 8 24
63. B.A. Gibson, and W.L. Kraus New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs Nat Rev Mol Cell Biol 13 2012 411 424
64. S. Vyas, M. Chesarone-Cataldo, T. Todorova, Y.H. Huang, and P. Chang A systematic analysis of the PARP protein family identifies new functions critical for cell physiology Nat Commun 4 2013 2240
65. L. Galluzzi, S.A. Aaronson, J. Abrams, E.S. Alnemri, D.W. Andrews, and E.H. Baehrecke Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes Cell Death Differ 16 2009 1093 1107
66. L. Galluzzi, I. Vitale, J.M. Abrams, E.S. Alnemri, E.H. Baehrecke, and M.V. Blagosklonny Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 Cell Death Differ 19 2012 107 120
67. J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, and M. Mark Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci U S A 94 1997 7303 7307
68. E. Pirinen, C. Canto, Y.S. Jo, L. Morato, H. Zhang, and K.J. Menzies Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle Cell Metab 19 2014 1034 1041
69. J. Michels, I. Vitale, M. Saparbaev, M. Castedo, and G. Kroemer Predictive biomarkers for cancer therapy with PARP inhibitors Oncogene 33 2013 3894 3907
70. K. Garber PARP inhibitors bounce back Nat Rev Drug Discov 12 2013 725 727
71. J. Murai, S.Y. Huang, B.B. Das, A. Renaud, Y. Zhang, and J.H. Doroshow Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 2012 5588 5599
72. B. Lupo, and L. Trusolino Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited Biochim Biophys Acta 1846 2014 201 215
73. J. Murai, S.Y. Huang, A. Renaud, Y. Zhang, J. Ji, and S. Takeda Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol Cancer Ther 13 2014 433 443
74. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
75. D.A. Jacob, M. Bahra, J.M. Langrehr, S. Boas-Knoop, R. Stefaniak, and J. Davis Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells J Gastroenterol Hepatol 22 2007 738 748
76. N. Magan, R.J. Isaacs, and K.M. Stowell Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells Anticancer Drugs 23 2012 627 637
77. J. Michels, I. Vitale, L. Senovilla, D.P. Enot, P. Garcia, and D. Lissa Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer Cell Cycle 12 2013 877 883
78. J.P. Palma, Y.C. Wang, L.E. Rodriguez, D. Montgomery, P.A. Ellis, and G. Bukofzer ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors Clin Cancer Res 15 2009 7277 7290
79. S.Y. Park, and Y.C. Cheng Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin Cancer Res 65 2005 3894 3902
80. B.B. Das, S.Y. Huang, J. Murai, I. Rehman, J.C. Ame, and S. Sengupta PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage Nucleic Acids Res 42 2014 4435 4449
81. F.A. Dungey, K.W. Caldecott, and A.J. Chalmers Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90 Mol Cancer Ther 8 2009 2243 2254
82. A.L. Russo, H.C. Kwon, W.E. Burgan, D. Carter, K. Beam, and X. Weizheng In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016 Clin Cancer Res 15 2009 607 612
83. J.M. Senra, B.A. Telfer, K.E. Cherry, C.M. McCrudden, D.G. Hirst, and M.J. O'Connor Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft Mol Cancer Ther 10 2011 1949 1958
84. Y.H. Ibrahim, C. Garcia-Garcia, V. Serra, L. He, K. Torres-Lockhart, and A. Prat PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition Cancer Discov 2 2012 1036 1047
85. A. Juvekar, L.N. Burga, H. Hu, E.P. Lunsford, Y.H. Ibrahim, and J. Balmana Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer Cancer Discov 2 2012 1048 1063
86. F.L. Rehman, C.J. Lord, and A. Ashworth The promise of combining inhibition of PI3K and PARP as cancer therapy Cancer Discov 2 2012 982 984
87. E. Gonzalez-Billalabeitia, N. Seitzer, S.J. Song, M.S. Song, A. Patnaik, and X.S. Liu Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition Cancer Discov 4 2014 896 904
88. C. Robert, and F.V. Rassool HDAC inhibitors: roles of DNA damage and repair Adv Cancer Res 116 2012 87 129
89. M. Braunstein, R.E. Sobel, C.D. Allis, B.M. Turner, and J.R. Broach Efficient transcriptional silencing in Saccharomyces cerevisiae requires a heterochromatin histone acetylation pattern Mol Cell Biol 16 1996 4349 4356
90. J. Luo, A.Y. Nikolaev, S. Imai, D. Chen, F. Su, and A. Shiloh Negative control of p53 by Sir2alpha promotes cell survival under stress Cell 107 2001 137 148
91. H. Vaziri, S.K. Dessain, E. Ng Eaton, S.I. Imai, R.A. Frye, and T.K. Pandita hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell 107 2001 149 159
92. J.T. Rodgers, C. Lerin, W. Haas, S.P. Gygi, B.M. Spiegelman, and P. Puigserver Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1 Nature 434 2005 113 118
93. X. Qiu, K. Brown, M.D. Hirschey, E. Verdin, and D. Chen Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation Cell Metab 12 2010 662 667
94. S. Someya, W. Yu, W.C. Hallows, J. Xu, J.M. Vann, and C. Leeuwenburgh Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction Cell 143 2010 802 812
95. A. Brunet, L.B. Sweeney, J.F. Sturgill, K.F. Chua, P.L. Greer, and Y. Lin Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase Science 303 2004 2011 2015
96. M.C. Motta, N. Divecha, M. Lemieux, C. Kamel, D. Chen, and W. Gu Mammalian SIRT1 represses forkhead transcription factors Cell 116 2004 551 563
97. L. Zhong, A. D'Urso, D. Toiber, C. Sebastian, R.E. Henry, and D.D. Vadysirisack The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha Cell 140 2010 280 293
98. E. Morselli, G. Marino, M.V. Bennetzen, T. Eisenberg, E. Megalou, and S. Schroeder Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome J Cell Biol 192 2011 615 629
99. E. Morselli, M.C. Maiuri, M. Markaki, E. Megalou, A. Pasparaki, and K. Palikaras Caloric restriction and resveratrol promote longevity through the sirtuin-1-dependent induction of autophagy Cell Death Dis 1 2010 e10
100. T. Eisenberg, S. Schroeder, A. Andryushkova, T. Pendl, V. Kuttner, and A. Bhukel Nucleocytosolic depletion of the energy metabolite acetyl-coenzyme a stimulates autophagy and prolongs lifespan Cell Metab 19 2014 431 444
101. G. Marino, F. Pietrocola, T. Eisenberg, Y. Kong, S.A. Malik, and A. Andryushkova Regulation of autophagy by cytosolic acetyl-coenzyme A Mol Cell 53 2014 710 725
102. P. Bai, C. Canto, A. Brunyanszki, A. Huber, M. Szanto, and Y. Cen PARP-2 regulates SIRT1 expression and whole-body energy expenditure Cell Metab 13 2011 450 460
103. P. Bai, C. Canto, H. Oudart, A. Brunyanszki, Y. Cen, and C. Thomas PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation Cell Metab 13 2011 461 468
104. C. Canto, R.H. Houtkooper, E. Pirinen, D.Y. Youn, M.H. Oosterveer, and Y. Cen The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity Cell Metab 15 2012 838 847
105. E.F. Fang, M. Scheibye-Knudsen, L.E. Brace, H. Kassahun, T. SenGupta, and H. Nilsen Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction Cell 157 2014 882 896
106. S.A. Andrabi, G.K. Umanah, C. Chang, D.A. Stevens, S.S. Karuppagounder, and J.P. Gagne Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis Proc Natl Acad Sci U S A 111 2014 10209 10214
107. R. Cerutti, E. Pirinen, C. Lamperti, S. Marchet, A.A. Sauve, and W. Li NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease Cell Metab 19 2014 1042 1049
108. J.A. Khan, F. Forouhar, X. Tao, and L. Tong Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery Expert Opin Ther Targets 11 2007 695 705
109. A. Le, C.R. Cooper, A.M. Gouw, R. Dinavahi, A. Maitra, and L.M. Deck Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proc Natl Acad Sci U S A 107 2010 2037 2042
110. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors Mol Cell Biol 29 2009 5872 5888
111. K. Holen, L.B. Saltz, E. Hollywood, K. Burk, and A.R. Hanauske The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor Invest New Drugs 26 2008 45 51
112. V.R. Fantin, J. St-Pierre, and P. Leder Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance Cancer Cell 9 2006 425 434
113. C.C. Chini, A.M. Guerrico, V. Nin, J. Camacho-Pereira, C. Escande, and M.T. Barbosa Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors Clin Cancer Res 20 2014 120 130
114. S. Okumura, T. Sasaki, Y. Minami, and Y. Ohsaki Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation J Thorac Oncol 7 2012 49 56
115. I. Bajrami, A. Kigozi, A. Van Weverwijk, R. Brough, J. Frankum, and C.J. Lord Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells EMBO Mol Med 4 2012 1087 1096
116. W. Jacot, S. Thezenas, R. Senal, C. Viglianti, A.C. Laberenne, and E. Lopez-Crapez BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer BMC Cancer 13 2013 523
117. A.M. Gonzalez-Angulo, K.M. Timms, S. Liu, H. Chen, J.K. Litton, and J. Potter Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer Clin Cancer Res 17 2011 1082 1089
118. A.R. Hartman, R.R. Kaldate, L.M. Sailer, L. Painter, C.E. Grier, and R.R. Endsley Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer Cancer 118 2012 2787 2795
119. E.H. Lips, L. Mulder, A. Oonk, L.E. van der Kolk, F.B. Hogervorst, and A.L. Imholz Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers Br J Cancer 108 2013 2172 2177
120. P. Aksoy, C. Escande, T.A. White, M. Thompson, S. Soares, and J.C. Benech Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38 Biochem Biophys Res Commun 349 2006 353 359
121. P. Aksoy, T.A. White, M. Thompson, and E.N. Chini Regulation of intracellular levels of NAD: a novel role for CD38 Biochem Biophys Res Commun 345 2006 1386 1392
122. D. Sidler, A. Brockmann, J. Mueller, U. Nachbur, N. Corazza, and P. Renzulli Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel Oncogene 31 2012 4095 4106
123. I. Vergote, N. Finkler, J. del Campo, A. Lohr, J. Hunter, and D. Matei Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer Eur J Cancer 45 2009 2324 2332
124. I. Vergote, N.J. Finkler, J.B. Hall, O. Melnyk, R.P. Edwards, and M. Jones Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer Int J Gynecol Cancer 20 2010 772 780
125. 2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase pi-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability J Med Chem 56 2013 4641 4655
126. M.Z. Kaczmarek, R.J. Holland, S.A. Lavanier, J.A. Troxler, V.I. Fesenkova, and C.A. Hanson Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells Leuk Res 38 2014 377 382
127. M. Laschak, K.D. Spindler, A.J. Schrader, A. Hessenauer, W. Streicher, and M. Schrader JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells BMC Cancer 12 2012 130
128. S.K. Choudhari, M. Chaudhary, S. Bagde, A.R. Gadbail, and V. Joshi Nitric oxide and cancer: a review World J Surg Oncol 11 2013 118
129. H. Sugita, M. Kaneki, S. Furuhashi, M. Hirota, H. Takamori, and H. Baba Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein Mol Cancer Res 8 2010 1152 1163
130. C.A. Caneba, L. Yang, J. Baddour, R. Curtis, J. Win, and S. Hartig Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells Cell Death Dis 5 2014 e1302
131. A.E. Maciag, R.J. Holland, Y. Kim, V. Kumari, C.E. Luthers, and W.S. Sehareen Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells J Med Chem 57 2014 2292 2302
132. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, and A.B. Hjelmeland Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
133. M. Venere, P. Hamerlik, Q. Wu, R.D. Rasmussen, L.A. Song, and A. Vasanji Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells Cell Death Differ 21 2014 258 269
134. B.S. Dwarakanath, D. Singh, A.K. Banerji, R. Sarin, N.K. Venkataramana, and R. Jalali Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects J Cancer Res Ther 5 Suppl 1 2009 S21 S26
135. J.F. Bean, Y.Y. Qiu, S. Yu, S. Clark, F. Chu, and M.B. Madonna Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma J Pediatr Surg 49 2014 981 984 discussion 4
136. Z. Liu, Y.Y. Zhang, Q.W. Zhang, S.R. Zhao, C.Z. Wu, and X. Cheng 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway Anticancer Drugs 25 2014 447 455
137. N. Goldin, L. Arzoine, A. Heyfets, A. Israelson, Z. Zaslavsky, and T. Bravman Methyl jasmonate binds to and detaches mitochondria-bound hexokinase Oncogene 27 2008 4636 4643
138. K. Birsoy, T. Wang, R. Possemato, O.H. Yilmaz, C.E. Koch, and W.W. Chen MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors Nat Genet 45 2013 104 108
139. S. Cardaci, S. Rizza, G. Filomeni, R. Bernardini, F. Bertocchi, and M. Mattei Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1 Cancer Res 72 2012 4526 4536
140. B. Salani, C. Marini, A.D. Rio, S. Ravera, M. Massollo, and A.M. Orengo Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II Sci Rep 3 2013 2070
141. C. Marini, B. Salani, M. Massollo, A. Amaro, A.I. Esposito, and A.M. Orengo Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer Cell Cycle 12 2013 3490 3499
142. J. Chen, J. Xie, Z. Jiang, B. Wang, Y. Wang, and X. Hu Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 Oncogene 30 2011 4297 4306
143. G. Marino, M. Niso-Santano, E.H. Baehrecke, and G. Kroemer Self-consumption: the interplay of autophagy and apoptosis Nat Rev Mol Cell Biol 15 2014 81 94
144. Z. Yang, and D.J. Klionsky Mammalian autophagy: core molecular machinery and signaling regulation Curr Opin Cell Biol 22 2010 124 131
145. Q. Sun, X. Chen, J. Ma, H. Peng, F. Wang, and X. Zha Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth Proc Natl Acad Sci U S A 108 2011 4129 4134
146. 1H-MRS and real-time hyperpolarized 13C-MRS studies PLOS ONE 9 2014 e92645
147. C. Ethier, M. Tardif, L. Arul, and G.G. Poirier PARP-1 modulation of mTOR signaling in response to a DNA alkylating agent PLoS ONE 7 2012 e47978
148. Q. Huang, and H.M. Shen To die or to live: the dual role of poly(ADP-ribose) polymerase-1 in autophagy and necrosis under oxidative stress and DNA damage Autophagy 5 2009 273 276
149. Q. Huang, Y.T. Wu, H.L. Tan, C.N. Ong, and H.M. Shen A novel function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and necrosis under oxidative stress Cell Death Differ 16 2009 264 277
150. R.A. Billington, A.A. Genazzani, C. Travelli, and F. Condorelli NAD depletion by FK866 induces autophagy Autophagy 4 2008 385 387
151. K. Legg Metabolic disease: identifying novel targets of resveratrol Nat Rev Drug Discov 11 2012 273
152. D. Lissa, L. Senovilla, S. Rello-Varona, I. Vitale, M. Michaud, and F. Pietrocola Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention Proc Natl Acad Sci U S A 111 2014 3020 3025
153. M.A. Iqbal, and R.N. Bamezai Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin PLoS ONE 7 2012 e36764
154. L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, and H. Zhang Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth Mol Cell 42 2011 719 730